Novocure
Novocure's revenue rose 8.3% to $655 million in fiscal 2025. Its operating margin was −23.5%, up from −28.2% a year earlier. Free cash flow was −$76 million. The diluted share count rose 3.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Novocure does
Novocure is an oncology company that makes a medical device for cancer. Its technology, Tumor Treating Fields, uses electric fields applied through the skin to exert physical forces that the company says kill cancer cells. Patients wear the device, which is sold under the Optune name.
It has three commercial devices. Optune Gio is approved in the United States for glioblastoma, an aggressive brain cancer, and in the European Union, the United Kingdom, Japan, Canada and other countries. Optune Lua is approved for metastatic non-small cell lung cancer and, in the US, for malignant pleural mesothelioma. Optune Pax is approved in the US for locally advanced pancreatic cancer. Novocure is also seeking approval for new uses, such as brain metastases from lung cancer.
Its revenue comes from patients using its devices, and it relies on payment from insurers and Medicare. Novocure says it has had only occasional and intermittent operating profits and has a history of substantial operating losses.
Its biggest risks, as it describes them
- It has only occasional operating profits and a history of substantial losses.
- Doctors, patients and insurers may not accept its products as fast as it expects.
- It may not secure or keep the coverage, billing codes and Medicare payment rates it needs.
- It depends on single-source suppliers for some components.
- Its clinical studies could be delayed, including by slow patient enrollment.
Income statement
Novocure lost money in fiscal 2025: a net loss of $136 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 209 | 115 | 241 | 164 | 94 |
| Debt incl. finance leases | 562 | 566 | 569 | 97 | 195 |
| Net debt (negative means net cash) | 353 | 450 | 328 | −67 | 102 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 1.4x | 1.3x | 1.6x | 0.3x | 0.6x |
| Interest coverage | −5.0x | −11.0x | −47.5x | −14.6x | −6.9x |
| Current ratio | 7.5x | 7.0x | 5.8x | 1.5x | 2.9x |
| Quick ratio | 7.4x | 6.8x | 5.6x | 1.4x | 2.7x |
Cash flow
Projections
Project Novocure's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Novocure shares on the open market, and 7 insiders sold $2.9 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Frank X LeonardChief Executive Officer | Sold | 34,273 | $17.93 | $614,515 | Form 4 |
| Jun 2, 2026 | Jeryl L HillemanDirector | Sold | 2,945 | $15.77 | $46,443 | Form 4 |
| Mar 5, 2026 | Mukund ParavasthuChief Operating Officer | Sold | 43,246 | $13.77 | $595,497 | Form 4 |
| Mar 4, 2026 | Uri WeinbergChf Medical and Innovation Ofr | Sold | 6,412 | $13.31 | $85,344 | Form 4 |
| Mar 4, 2026 | Frank X LeonardChief Executive Officer | Sold | 5,607 | $13.31 | $74,629 | Form 4 |
| Mar 4, 2026 | Mukund ParavasthuChief Operating Officer | Sold | 5,377 | $13.31 | $71,568 | Form 4 |
| Mar 4, 2026 | Michal Nath PuriChief Human Resources Officer | Sold | 1,100 | $13.31 | $14,641 | Form 4 |
| Mar 3, 2026 | William F DoyleExecutive Chairman, Director | Sold | 71,887 | $12.98 | $933,086 | Form 4 |
| Mar 2, 2026 | Frank X LeonardChief Executive Officer | Sold | 7,232 | $13.49 | $97,560 | Form 4 |
| Mar 2, 2026 | Uri WeinbergChf Medical and Innovation Ofr | Sold | 3,272 | $13.33 | $43,616 | Form 4 |
| Mar 2, 2026 | Mukund ParavasthuChief Operating Officer | Sold | 408 | $13.49 | $5,504 | Form 4 |
| Feb 27, 2026 | Frank X LeonardChief Executive Officer | Sold | 9,734 | $13.66 | $132,966 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 1 of 9 | 5 of 9 | 4 of 9 |
| Rule of 40 | −25.0% | 7.4% | −3.3% |
| Altman Z'' | 1.21 | −1.67 | −2.29 |
| Accruals ratio | −11.4% | −11.9% | −8.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 1 of 9 | 5 of 9 | 4 of 9 |
Compare
Put Novocure side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Novocure | FY25 | 8.3% | −23.5% | −11.6% | −33.0% | — | 4 | |
| TransMedics Group | FY25 | 37.1% | 17.9% | 22.1% | 27.5% | −0.2x | 7 | Compare |
| UFP Technologies | FY25 | 19.5% | 15.3% | — | 14.4% | 1.0x | 5 | Compare |
| iRhythm | FY25 | 26.2% | −7.7% | 4.6% | −12.4% | — | 5 | Compare |
| Bioventus | FY25 | −0.9% | 9.5% | 12.7% | 11.1% | 2.5x | 8 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 83 | 177 | 248 | 351 | 494 | 535 | 538 | 509 | 605 | 655 |
| Revenue growth | 150.5% | 113.6% | 40.1% | 41.6% | 40.7% | 8.2% | 0.5% | −5.3% | 18.8% | 8.3% |
| Gross profit | 37 | 121 | 168 | 263 | 388 | 420 | 423 | 381 | 468 | 488 |
| Research and development | 42 | 38 | 51 | 79 | 132 | 201 | 206 | 223 | 210 | 224 |
| Operating income | −115 | −39 | −34 | −1 | 30 | −44 | −90 | −233 | −170 | −154 |
| Net income | −132 | −62 | −64 | −7 | 20 | −58 | −92 | −207 | −169 | −136 |
| Diluted EPS (US$) | −1.54 | −0.70 | −0.69 | −0.07 | 0.18 | −0.56 | −0.88 | −1.95 | −1.56 | −1.22 |
| Diluted shares (millions) | 86 | 88 | 92 | 97 | 109 | 103 | 105 | 106 | 108 | 112 |
| Cash flow | ||||||||||
| Cash from operations | −108 | −33 | −2 | 27 | 99 | 83 | 31 | −73 | −26 | −49 |
| Capital expenditure | 6 | 7 | 7 | 10 | 15 | 24 | 21 | 27 | 43 | 27 |
| Free cash flow | −113 | −40 | −9 | 16 | 84 | 59 | 9 | −100 | −69 | −76 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 22 | 27 | 40 | 52 | 76 | 95 | 107 | 116 | 160 | 105 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 100 | 79 | 141 | 177 | 235 | 209 | 115 | 241 | 164 | 94 |
| Debt incl. finance leases | 0 | 0 | 0 | 149 | 430 | 562 | 566 | 569 | 97 | 195 |
| Total assets | 282 | 265 | 340 | 479 | 1,052 | 1,140 | 1,192 | 1,146 | 1,241 | 804 |
| Total liabilities | 140 | 152 | 228 | 262 | 576 | 729 | 750 | 784 | 881 | 464 |
| Shareholders' equity | 142 | 114 | 112 | 218 | 476 | 410 | 441 | 362 | 360 | 340 |
| Margins and ratios | ||||||||||
| Gross margin | 44.2% | 68.6% | 67.7% | 74.8% | 78.5% | 78.5% | 78.6% | 74.8% | 77.3% | 74.5% |
| Operating margin | −139.1% | −22.2% | −13.6% | −0.3% | 6.2% | −8.3% | −16.6% | −45.7% | −28.2% | −23.5% |
| Net margin | −159.1% | −34.8% | −25.6% | −2.1% | 4.0% | −10.9% | −17.2% | −40.6% | −27.9% | −20.8% |
| Free cash flow margin | −136.7% | −22.9% | −3.5% | 4.6% | 17.0% | 10.9% | 1.8% | −19.7% | −11.4% | −11.6% |
| Rule of 40 (growth + FCF margin) | 13.9% | 90.7% | 36.7% | 46.2% | 57.8% | 19.2% | 2.3% | −25.0% | 7.4% | −3.3% |
| Return on capital | −104.4% | −79.7% | — | −0.9% | 7.1% | −4.9% | −8.6% | −23.3% | −27.4% | −33.0% |
| Return on equity | −67.1% | −48.2% | −56.3% | −4.4% | 5.7% | −13.2% | −21.7% | −51.5% | −46.7% | −38.9% |
| Return on assets | −44.7% | −22.5% | −21.0% | −1.8% | 2.6% | −5.3% | −7.9% | −17.7% | −14.1% | −13.3% |
| Net debt to EBITDA | — | — | — | −3.7x | 4.9x | — | — | — | — | — |